News
Contributing to the World’s Drug Discovery Research by Promoting the Utilization of Medical Big DataStrengthening Collaboration with IQVIA and TriNetX for Global Expansion
- November 2, 2021
Medical Data Vision Co., Ltd. (“MDV”) (Chiyoda-ku, Tokyo, President: Hiroyuki Iwasaki), owner of one of the largest medical databases in Japan, is promoting the utilization of medical big data to contribute to international drug discovery research through business alliance agreements with global companies.
We are proud to announce that MDV has entered into a business alliance agreement with the following two companies:
IQVIA Solutions Japan, K.K., a Japanese office of IQVIA Inc. (North Carolina)
IQVIA provides access to worldwide RWD and analytical insights through the E360™ platform, and MDV data is now integrated into the E360™ global RWD network covering more than 1billion non-identified patients across 12 markets.
TriNetX, LLC. (Massachusetts)
TriNetX provides clinical trial platform TriNetX Live™, which MDV data has been integrated as Japan Claims Network.
MDV’s medical database has a total of 37.71 million anonymous patients in Japan (as of October 31, 2021). Medical information in the database is made anonymous at the source before it is shared with MDV. The collaboration with IQVIA and TriNetX will be strengthened to meet the strong demand for Japanese medical data from around the world for research leading to drug discovery. Utilizing the international networks of both companies will accelerate the utilization of MDV medical data outside Japan to help find ways to improve patient outcomes, lower healthcare costs and improve patient access to care.
IQVIA provides data, technology, advanced analytics, and expertise to transform business and patient outcomes in over 100 countries and regions around the world. By using MDV data through IQVIA RWD platform the E360™, overseas healthcare stakeholders can optimize treatment understanding, clinical development, market access and evidence generation in Japan. In addition, cross country comparisons and analytics can be allowed efficiently by using OMOP converted MDV data.
TriNetX has partnered with medical institutions in 29 countries around the world to build a global health research network with more than 400 million patients and has the world’s leading clinical trial platform. Together with its shareholder, Mitsui & Co., Ltd. (Chiyoda-ku, Tokyo), TriNetX will promote the use of MDV data in global clinical trials.